首页 › 头颈鳞状细胞癌 › 威斯康星州 › Milwaukee
Milwaukee WI 头颈鳞状细胞癌临床试验
13项针对 头颈鳞状细胞癌的研究正在 Milwaukee及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
招募中3 期
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Medical College of Wisconsin, Milwaukee
- 以及另外 8 项
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
招募中2/3 期
- Site # 0153, Milwaukee
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #33, Milwaukee
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
招募中3 期
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- 以及另外 8 项
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
招募中1 期
- Research Site, Milwaukee
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
招募中2 期
- Medical College of Wisconsin, Milwaukee
- ProHealth Waukesha Memorial Hospital, Waukesha · 距离 17 英里
- UW Cancer Center at ProHealth Care, Waukesha · 距离 17 英里
- 以及另外 1 项
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
招募中2 期
- Medical College of Wisconsin, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 距离 11 英里
- Froedtert Menomonee Falls Hospital, Menomonee Falls · 距离 14 英里
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
招募中1/2 期
- Froedtert & MCW Cancer Center, Milwaukee
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
招募中2 期
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- 以及另外 5 项
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
招募中2/3 期
- Medical College of Wisconsin, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 距离 11 英里
- Froedtert and MCW Moorland Reserve Health Center, New Berlin · 距离 11 英里
- 以及另外 1 项
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
招募中2 期
- Medical College of Wisconsin, Milwaukee
- Zablocki Veterans Administration Medical Center, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 距离 11 英里
- 以及另外 1 项
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
招募中3 期
- Medical College of Wisconsin, Milwaukee
- Drexel Town Square Health Center, Oak Creek · 距离 11 英里
- Froedtert and MCW Moorland Reserve Health Center, New Berlin · 距离 11 英里
- 以及另外 1 项
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
招募中1/2 期
- Froedtert & the Medical College of Wisconsin, Milwaukee
其他城市的 头颈鳞状细胞癌试验
- Houston, TX47 项研究
- Los Angeles, CA42 项研究
- Boston, MA40 项研究
- New York City, NY39 项研究
- Nashville, TN39 项研究
- St. Louis, MO28 项研究
- Arlington, VA26 项研究
- Chicago, IL26 项研究
- Philadelphia, PA26 项研究
- Atlanta, GA24 项研究
- San Antonio, TX22 项研究
- New Haven, CT22 项研究
Milwaukee的其他研究
- 乳腺癌23 项研究
- 癌症（所有类型）22 项研究
- 非小细胞肺癌22 项研究
- 多发性骨髓瘤21 项研究
- 肺癌21 项研究
- 前列腺癌20 项研究
- 滤泡性淋巴瘤19 项研究
- 非霍奇金淋巴瘤18 项研究
- 胰腺癌18 项研究
- 急性髓系白血病17 项研究
- 卵巢癌17 项研究
- 弥漫性大B细胞淋巴瘤16 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。